The elevation of oxidative stress through MTHFD1L knockdown or the use of methotrexate, an antifolate drug, sensitizes cancer cells to sorafenib, a targeted therapy for hepatocellular carcinoma (Lee et al., 2017). Here, MTHFD1L is linked to hepatocellular carcinoma.